I agree that information about the patients who subsequently received another I-O drug and not reaching the MOS was good; however, that was in a PR awhile back and not part of the most recent PR and to the message you responded to.
I stated the same thing in my last post about those patients; however, how meaningful is it in increasing shareholder value? Wouldn't there be a need to run more clinical trials? There is no way that anything near commercialization is a few years away in regards to Bavituximab. For example, the NCCN trials, those are going to take a few years themselves. So even with rose colored glasses.. maybe 6-8 years away?
Astrazenca seems to be doing well with their IO program and we have not heard a peep from PPHM in almost 2 years since the so called Partnership was announced.
Doesn't it seem odd that Peregrine moves so slow in monetizing anything? Do you think it is the Product or the Leadership?
Market Data 
Markets 
AI
